Literature DB >> 10764308

Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival.

W W Douglas1, J H Ryu, D R Schroeder.   

Abstract

The clinical records of 487 patients seen at Mayo Clinic Rochester (MCR) during 1994 through 1996 who were diagnosed as having idiopathic pulmonary fibrosis of the usual interstitial pneumonia type (IPF/UIP) were reviewed. Computed tomography (CT) had been done in 94.7% of patients and surgical open lung biopsy (OLB) in 20.3%. Median survival was 3.2 yr. We compared survival as a function of treatment program, based on intent to treat at the time of the initial contact within the study window. Treatment advised included colchicine alone in 167, no therapy in 157, prednisone at maintenance dosages alone in 54, colchicine plus prednisone in 71, and other programs in 38. Oxygen therapy was advised in 133 patients. By univariate analysis, worse survival was associated with prednisone therapy compared with no therapy, and with oxygen therapy compared with no oxygen therapy. However, on multivariate analysis, worse survival was associated with older age, male gender, lower diffusing capacity for carbon monoxide (DL(CO)), lower alveolar volume (VA), and a history of worsening pulmonary function. When adjustment was made for these factors, there was no significant difference in survival between those patients treated with colchicine or prednisone and those on no therapy, and no difference between those on oxygen therapy and those without oxygen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764308     DOI: 10.1164/ajrccm.161.4.9907002

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  34 in total

1.  [Pulmonary fibrosis. Classification, diagnosis, therapy].

Authors:  U Costabel; J Guzman
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Authors:  Richard H Gomer; Mark L Lupher
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

4.  A critical assessment of treatment options for idiopathic pulmonary fibrosis.

Authors:  Nirav R Shah; Paul Noble; Robert M Jackson; Talmadge E King; Steven D Nathan; Maria Padilla; Ganesh Raghu; Melissa Bruce Rhodes; Marvin Schwarz; Gregory Tino; Robert W Dubois
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2005-10       Impact factor: 0.670

Review 5.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

6.  Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.

Authors:  Harold R Collard; James E Loyd; Talmadge E King; Lisa H Lancaster
Journal:  Respir Med       Date:  2007-05-16       Impact factor: 3.415

7.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 8.  Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.

Authors:  Talmadge E King
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

9.  Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration.

Authors:  Hidekata Yasuoka; Zhihong Zhou; Joseph M Pilewski; Tim D Oury; Augustine M K Choi; Carol A Feghali-Bostwick
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

10.  Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia.

Authors:  C Jakubzick; E S Choi; S L Kunkel; H Evanoff; F J Martinez; R K Puri; K R Flaherty; G B Toews; T V Colby; E A Kazerooni; B H Gross; W D Travis; C M Hogaboam
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.